ArticleFrontiers in cardiovascular medicine2026
Combined assessment of fibrinogen-to-platelet ratio and ApoB/ApoA1 ratio for pre-angiographic risk stratification of severe multivessel coronary disease in NSTEMI.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Residual inflammation and dysregulated lipid metabolism are closely associated with the extent of severe multivessel coronary disease (MVD) in patients with non-ST-segment elevation myocardial infarction (NSTEMI). The fibrinogen-to-platelet ratio (FPR) and the apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) ratio reflect these two residual risk pathways, respectively, whereas the clinical value of their combined assessment for pre-angiographic identification of severe MVD remains to be evaluated. Objective: To evaluate the incremental value of combining FPR with the ApoB/ApoA1 ratio for pre-angiographic identification of severe MVD in patients with NSTEMI and to develop an adjunctive risk-stratification model. Methods: This single-center retrospective study included 580 patients with NSTEMI who underwent coronary angiography. Correlation analyses, logistic regression, and restricted cubic spline models were used to assess the associations between the two biomarkers and MVD. The area under the receiver operating characteristic curve (AUC), continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate the incremental value of the biomarkers. A nomogram was developed and internally validated using bootstrap resampling. Decision curve analysis (DCA) was performed to assess net clinical benefit, and subgroup analyses were conducted. Results: FPR remained independently and positively associated with severe MVD, with an approximately linear dose-response relationship; the association of the ApoB/ApoA1 ratio was attenuated after full adjustment, although it showed complementary value in patients with a very high coronary lesion burden. With the combined model, the AUC increased from 0.683 to 0.719, while the continuous NRI and IDI were 0.488 and 0.037, respectively; adding the ApoB/ApoA1 ratio to the model containing FPR did not significantly improve the AUC ( Conclusion: FPR is an important adjunctive biomarker for the pre-angiographic identification of severe MVD in patients with NSTEMI, whereas the ApoB/ApoA1 ratio provides complementary reclassification information. The nomogram incorporating both biomarkers may facilitate pre-angiographic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.